Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant (PAUSE)
Source: View publication →
A standardized protocol for interrupting and resuming direct oral anticoagulants without heparin bridging around the time of elective surgery was safe, resulting in very low rates of major bleeding and arterial thromboembolism.
Key Findings
Study Design
Study Limitations
Clinical Significance
The PAUSE trial fundamentally changed perioperative practice by demonstrating that patients on DOACs for atrial fibrillation can safely undergo surgery using a simple, standardized interruption schedule based on procedural bleeding risk and renal function, without the need for potentially harmful heparin bridging or routine preoperative coagulation testing.
Historical Context
Prior to the PAUSE trial, the perioperative management of DOACs was highly variable and heavily influenced by historical practices of 'heparin bridging' commonly used for warfarin. After the BRIDGE trial (2015) showed that bridging warfarin increased bleeding without proportionally reducing thromboembolism, there was an urgent need to establish an evidence-based protocol for DOACs, which have a much shorter half-life. PAUSE provided the definitive clinical framework for modern perioperative DOAC management.
Guided Discussion
High-yield insights from every perspective
Why does the pharmacokinetic profile of direct oral anticoagulants (DOACs) make bridging therapy with low-molecular-weight heparin unnecessary and potentially harmful compared to traditional perioperative management with warfarin?
Key Response
DOACs have a rapid onset of action (1-4 hours) and a short half-life (typically 12-14 hours), meaning their anticoagulant effect predictably and quickly dissipates upon cessation and resumes rapidly upon restarting. Warfarin, by contrast, takes days to wash out and re-establish therapeutic levels. Bridging DOACs simply overlaps two rapid-acting anticoagulants, exponentially increasing the risk of major bleeding without providing additional protection against thrombosis.
When applying the PAUSE protocol to determine when to interrupt a DOAC prior to an elective procedure, what two primary patient and procedure-specific variables must you assess, and how does the choice of dabigatran alter this algorithm compared to apixaban or rivaroxaban?
Key Response
The two key variables are the procedure's bleeding risk (low vs. high) and the patient's creatinine clearance (CrCl). Dabigatran is predominantly renally cleared (80%), requiring a specifically extended interruption time (e.g., 4 days for high bleed risk) in patients with CrCl less than 50 mL/min compared to apixaban and rivaroxaban, which have significantly lower renal clearance.
The PAUSE study measured preoperative residual DOAC levels in a subset of patients, finding that a small percentage still had levels greater than 50 ng/mL despite strict protocol adherence. How should this finding influence your perioperative management of a patient scheduled for high-risk neuraxial anesthesia?
Key Response
While the vast majority of patients had negligible residual levels, the few with levels greater than 50 ng/mL pose a severe risk for epidural or spinal hematoma. For procedures where even microscopic bleeding is catastrophic (neuraxial anesthesia), fellows must recognize that clinical protocols are population-based. Unpredictable individual variations in clearance may necessitate checking specific anti-Xa levels, a dilute thrombin time, or further extending the interruption window to guarantee safe neuraxial puncture.
Despite robust evidence from the BRIDGE and PAUSE trials demonstrating the harms of heparin bridging, many surgical colleagues remain hesitant to leave patients 'unprotected' off anticoagulation. How can you use the PAUSE data to effectively reframe perioperative DOAC management during surgical risk discussions?
Key Response
The teaching point focuses on shifting the paradigm from 'preventing strokes' to 'doing no harm through bleeding.' PAUSE demonstrated a 30-day stroke risk of less than 1 percent without any heparin bridging. Attendings must emphasize that the perioperative hypercoagulable state is best managed by minimizing surgical bleeding, because post-operative bleeding forces a delayed resumption of the DOAC, which is the actual primary driver of perioperative stroke.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The PAUSE trial was designed as a prospective, single-arm management cohort study rather than a randomized controlled trial comparing standardized interruption against individualized 'usual care' or bridging. What are the methodological justifications and potential threats to internal validity inherent in choosing this study design?
Key Response
A randomized trial was deemed practically challenging and ethically questionable given the established harms of bridging from the BRIDGE trial for warfarin and the lack of clinical equipoise for DOAC bridging. However, the lack of a concurrent control group is a threat to internal validity; the exceptionally low event rates could be influenced by selection bias (enrolling lower-risk, elective surgery patients) or temporal trends, limiting definitive causal claims about the protocol's superiority over individualized care.
As a peer reviewer assessing the external validity of the PAUSE protocol, which specific patient populations were excluded or underrepresented in this cohort, and how should these exclusions impact the editorial decision regarding the manuscript's claims of real-world applicability?
Key Response
A critical reviewer would flag that PAUSE excluded patients with mechanical heart valves, recent (within 3 months) thromboembolic events, and severe renal impairment (CrCl less than 25-30 mL/min). Thus, the protocol cannot be universally applied to all anticoagulated patients. Highlighting these exclusions is crucial for an editor to ensure the authors explicitly define their study's boundaries and do not overstate the algorithm's safety in highly complex or inherently unstable patient populations.
How does the prospective validation of the PAUSE algorithm influence the level of evidence for current perioperative guidelines (such as the ACCP or ACC/AHA guidelines), and does this study provide sufficient evidence to support a strong recommendation against routine perioperative DOAC bridging?
Key Response
PAUSE elevates the evidence from expert consensus and retrospective data to high-quality prospective cohort data. Current guidelines (like the 2022 ACCP guidelines on perioperative management) strongly recommend against bridging DOACs. PAUSE solidifies this with a standardized, reproducible, pharmacokinetic-driven algorithm, transitioning the evidence base to Level B-R (or B-NR depending on the grading system) and serving as the foundational prospective evidence to firmly anchor Class 1 recommendations against DOAC bridging in elective procedures.
Clinical Landscape
Noteworthy Related Trials
ARISTOTLE Trial
Tested
Apixaban 5mg twice daily
Population
Patients with atrial fibrillation and at least one additional risk factor for stroke
Comparator
Warfarin (target INR 2.0-3.0)
Endpoint
Stroke or systemic embolism
BRIDGE Trial
Tested
No bridging with low-molecular-weight heparin
Population
Atrial fibrillation patients on warfarin undergoing elective surgery
Comparator
Bridging with dalteparin
Endpoint
Arterial thromboembolism and major bleeding
RE-VERSE AD Trial
Tested
Idarucizumab (5g intravenous)
Population
Dabigatran-treated patients with serious bleeding or requiring urgent surgery
Comparator
None (single-arm study)
Endpoint
Maximum percentage reversal of the anticoagulant effect of dabigatran
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis